Alterity Therapeutics (PRNAD) Accumulated Expenses (2015 - 2025)

Alterity Therapeutics (PRNAD) has reported Accumulated Expenses for 6 consecutive years, with $1.1 million the latest figure, recorded in Q2 2025.

• In Q2 2025, Accumulated Expenses fell 69.17% year-over-year to $1.1 million; the TTM figure through Jun 2025 stood at $1.1 million (down 69.17% YoY), while the FY2025 annual figure was $1.1 million, up 885.89% from the prior year.
• Accumulated Expenses came in at $1.1 million for Q2 2025 at Alterity Therapeutics, down from $3.5 million in the prior quarter.
• The five-year high for Accumulated Expenses was $3.5 million in Q2 2024, with the low at $550340.7 in Q2 2021.
• Average Accumulated Expenses over 5 years is $1.5 million, with a median of $1.1 million recorded in 2025.
• Across the five-year window, Accumulated Expenses jumped 259.09% in 2024 and plunged 69.17% in 2025, its largest moves.
• Year by year, Accumulated Expenses stood at $550340.7 in 2021, then soared by 168.95% to $1.5 million in 2022, then plunged by 34.15% to $974676.7 in 2023, then surged by 259.09% to $3.5 million in 2024, then sank by 69.17% to $1.1 million in 2025.
• According to Business Quant data, Accumulated Expenses over the past three periods registered $1.1 million, $3.5 million, and $974676.7 for Q2 2025, Q2 2024, and Q2 2023 respectively.